Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in Pediatric HSCT-Associated Thrombotic Microangiopathy
2023-507850-33-00Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of ravulizumab in transplant-associated thrombotic microangiopathy (TA-TMA), sponsored by Alexion Pharmaceuticals. Primary endpoint: TMA response. Started Feb 2021; status: completed.
02
Drugs
ravulizumab
03
Conditions
transplant-associated thrombotic microangiopathy (TA-TMA)
Beyond the preview
Go deeper on 2023-507850-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507850-33-00.